Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasm Metastasis 1Breast Neoplasms 1

Interventions

pembrolizumab 30Capecitabine 24Bevacizumab 23Cyclophosphamide 22Gemcitabine 21Paclitaxel 20Nivolumab 19Fluorouracil 19Docetaxel 18aldesleukin 17Leucovorin 17Irinotecan 17Oxaliplatin 15Interleukin-2 14Radiosurgery 13Cisplatin 13Cetuximab 13fludarabine 12Carboplatin 12Albumin-Bound Paclitaxel 11fludarabine phosphate 10Ipilimumab 10Drug Therapy 10Doxorubicin 10Sunitinib 9Radiotherapy 9Everolimus 9130-nm albumin-bound paclitaxel 9Trastuzumab 8Temozolomide 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neoplasm Metastasis × onapristone × Clear all
NCT04738292 2024-05-03

Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)

University of Wisconsin, Madison

Phase 2 Terminated
11 enrolled 10 charts
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡